Skin cancer patients appear to fare better if they receive immunotherapy before their cancers are surgically removed, a pair of clinical trials show.
In fact, some do so well that their immune system essentially dissolves their tumors, potentially removing the need for surgery, researchers said.
About half of skin cancer patients who received the immunotherapy drug cemiplimab (Libtayo) had a complete response to the medication, meaning doctors could find no cancer cells left at the tumor site following the advance treatment, according to one of the clinical trials.